Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Although much research on kids at risk to develop psychopathy has focused on callous-unemotional traits, this streamlined ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

Today's medical AI systems represent not just a new diagnostic tool, but a new kind of medical reasoning altogether, writes ...

In this webinar, sponsored by IPG Health, we will explore the role that cell and gene therapies can play in treating rare diseases, the unique challenges faced by pharmaceutical companies, healthcare ...

We are now entering the third decade of the 21st Century, and, especially in the last years, the achievements made by ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

The Muscular Dystrophy Association (MDA) is honoring a longtime researcher and an LGMD patient advocate with its 2025 Legacy ...

Since taking office for his second term on Jan. 20, 2025, President Donald Trump has issued a series of executive orders (EOs) aimed at ...

AmplifyBio, a leading preclinical CRO and CDMO played a pivotal role in shaping discussions at Phacilitate’s Advanced Therapy ...